Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $6.70, but opened at $7.25. Oxford BioMedica shares last traded at $7.25, with a volume of 600 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Zacks Research upgraded shares of Oxford BioMedica to a “hold” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Hold rating. According to data from MarketBeat, the company has an average rating of “Hold”.
Get Our Latest Stock Analysis on Oxford BioMedica
Oxford BioMedica Price Performance
The company’s 50-day simple moving average is $6.79 and its 200-day simple moving average is $7.59.
About Oxford BioMedica
Oxford BioMedica plc is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company works with biotechnology and pharmaceutical customers to develop, manufacture and test viral vectors and other biological materials used in advanced therapies.
Its capabilities include process and analytical development, clinical and commercial manufacturing, quality control, regulatory support and technology transfer. Oxford BioMedica has particular expertise in lentiviral vectors, which are used to deliver genetic material into cells, and also provides services involving adeno-associated virus and other viral-vector platforms.
Founded in 1995 and headquartered in Oxford, England, the company serves customers internationally across the pharmaceutical and biotechnology industries.
Further Reading
- Five stocks we like better than Oxford BioMedica
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
